Stentrode is the only implantable brain-computer interface that does not require open brain surgery and is currently in clinical trials SAN FRANCISCO & NEW YORK & MELBOURNE, Australia--(BUSINESS WIRE) ...

California Start-up Synchron recently published its study and findings in the success of the "Stentrode" Brain chips implanted in the blood vessels of paralyzed and disabled patients to help them ...

SAN FRANCISCO and NEW YORK CITY and MELBOURNE, Australia, Sept. 20 2019 /PRNewswire/ -- Synchron Inc. today announced the first successful clinical implantation of the Stentrode®, a minimally-invasive ...

Synchron, the startup behind an FDA breakthrough neuroprosthesis device that aims to give patients with paralysis the ability to control digital devices with their thoughts, has been cleared by the ...

NEW YORK--(BUSINESS WIRE)--Synchron, a brain computer interface (BCI) company, today announced the results from a study in which four people with ALS received an implant of Synchron’s Stentrode™ ...

US-based Synchron has secured $200m in a Series D funding round to drive the commercial rollout of its Stentrode brain-computer interface (BCI) platform and aid in the creation of next-generation ...

One year down, a lifetime to go. New results from Synchron’s first human study of its brain-computer interface system—a permanent, stent-like implant—found that one year after the device’s placement, ...

Blood vessel brain implant brings mind control to Apple's spatial computer Rather than cut a chunk of skull away to install a brain-computer interface like Neuralink, Synchron feeds electrodes up ...

Synchron Inc.'s recent $200 million raise for its Stentrode brain-computer interface platform comes at a pivotal time for the technology. Advances in BCI development, ongoing clinical trials and ...

Neurovascular bioelectronics medicine company Synchron Inc. has received good news in the form of a breakthrough device designation for its Stentrode. The U.S. FDA granted the designation for the ...